Eledon Pharmaceuticals announced that updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for kidney transplant rejection prevention will be presented at the World Transplant Congress taking place in San Francisco from August 2-6, 2025. The oral presentation will feature updated results from approximately 30 kidney transplant recipients and will be delivered by Dr. John Gill from the University of British Columbia.
Clinical Trial Progress and Presentation Details
The presentation, titled "Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study," is scheduled for Wednesday, August 6, 2025, from 10:00 a.m. to 11:15 a.m. PT during the "Kidney Novel Immunosuppressant Strategies" session. The selection for an oral presentation at this major transplant conference suggests the data warrants attention from the transplant community.
Tegoprubart is an anti-CD40L antibody that targets CD40L (CD154), a well-established therapeutic target for transplantation. The mechanism works by blocking co-stimulatory signals needed for T-cell activation, potentially offering a more targeted approach than conventional immunosuppressants.
Expanding Therapeutic Applications
Beyond kidney transplantation, Eledon is exploring expanded applications for tegoprubart. New preclinical data utilizing tegoprubart for the prevention of rejection in non-human primates undergoing liver transplantation will be presented by Dr. Andrew Adams from the University of Minnesota in a poster session on Sunday, August 3, 2025, at 3:30 p.m. PT. The poster is titled "Anti-CD154 Facilitates Long-Term Liver Allograft Survival in Non-Human Primates."
Strategic Positioning and Market Approach
Eledon will sponsor a satellite symposium at the World Transplant Congress titled "What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?" scheduled for Sunday, August 3, at 1:00 pm PT. The faculty includes prominent transplant specialists: Allan Kirk, MD, from Duke University School of Medicine; Oriol Bestard, MD, PhD, from Vall d'Hebron University Hospital; John Gill, MD, MS, from University of British Columbia; Alexandre Loupy, MD, PhD, from Necker Hospital; and Deirdre Sawinski, MD, from Weill Cornell Medical College.
This strategic symposium suggests Eledon is positioning tegoprubart in the context of long-term outcomes versus short-term rejection prevention, potentially differentiating their approach from competitors. The company appears to be establishing tegoprubart's value proposition around improved long-term graft function rather than solely focusing on immediate rejection prevention.
The current Phase 1b trial represents an early-stage study primarily focused on safety and preliminary efficacy signals rather than definitive outcomes. However, the breadth of data being presented across both kidney and liver transplantation applications indicates Eledon's comprehensive approach to developing tegoprubart as a novel immunosuppressive therapy for solid organ transplantation.
